世界科学技术-中医药现代化2025，Vol.27Issue(3)：809-814,6.DOI:10.11842/wst.20240407002
基于中西医临床病症特点的骨筋膜室综合征动物模型评价与分析
Evaluation and Analysis of Animal Model of Bone Compartment Syndrome Based on Clinical Disease Characteristics of Traditional Chinese and Western Medicine
摘要
Abstract
Osteofascial compartment syndrome(OCS)is a serious complication frequently occurring in the orthopedic department,and delayed treatment may result in irreversible limb damage.With the increase of traffic trauma accidents in modern times,the incidence and disability risk of OCS have increased,so it has been widely concerned by medicine.Based on the clinical characteristics of OCS in traditional Chinese and Western medicine,this paper summarized the commonly used animal models of OCS by referring to CNKI and PubMed literature,and evaluated the data of the animal models'coincidence in combination with clinical diagnostic criteria,analyzed the comprehensive characteristics of the models,and provided a feasible reference for the animal models in the treatment of OCS in modern traditional Chinese and Western medicine.The results showed that the most commonly used OCS model was the rabbit model,which was constructed with pressure damage.Most of the methods are provided by foreign research institutes,but there is no research on the model of combining disease and syndrome of OCS with traditional Chinese and Western medicine,which brings certain obstacles to disease research.Therefore,this study summarized the advantages and disadvantages of the existing model of OCS through a large number of literature analysis,and put forward suggestions for the preparation of the model of combining traditional Chinese and Western medicine with fundamental theories of traditional Chinese and Western medicine.关键词
骨筋膜室综合征/动物模型/吻合度分析/指标评价Key words
Osteofascial compartment syndrome/Animal model/Anastomosis analysis/Index evaluation分类
医药卫生引用本文复制引用
刘雨倩,王嘉,张路锦,朱飞鹏,苗明三..基于中西医临床病症特点的骨筋膜室综合征动物模型评价与分析[J].世界科学技术-中医药现代化,2025,27(3):809-814,6.基金项目
河南省重大专项(221100310400):基于"核心功效-生物活性-物质基础"的八大宛药质量标准体系建立,负责人:苗明三 （221100310400）
河南省国际合作重点项目(231111521200):豫药外用防治免疫性疾病的现代研究,负责人:苗明三 （231111521200）
国家中医药管理局联合开放课题(GZYKJS-2022-040-1):仲景经方保健中药功能评价与应用示范,负责人:苗明三. （GZYKJS-2022-040-1）
